Business Overview: Structure Therapeutics Inc. (NASDAQ: GPCR)

---

Executive Summary

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule drugs that target G-protein coupled receptors (GPCRs) — the same receptor family exploited by injectable GLP-1 blockbusters like Ozempic and Wegovy, but via a pill rather than a weekly injection.

Its lead candidate, aleniglipron (GSBR-1290), is an oral, "biased" GLP-1 receptor agonist designed to activate beneficial G-protein signaling while minimizing β-arrestin signaling associated with side effects. In Phase 2b trials, aleniglipron produced placebo-adjusted weight loss of up to 11.3% at 36 weeks in the core ACCESS study and up to 15.3% at 36 weeks in the higher-dose ACCESS II study. The company plans to begin Phase 3 trials in the second half of 2026. Structure Therapeutics matters as one of the more clinically advanced challengers in the race to bring an effective, convenient oral GLP-1 therapy to market — a prize large enough that Roche/Genentech paid $100 million upfront in December 2025 just to license a related but distinct molecule class from Structure's discovery platform.

---

1. Core Business Model & How They Work

[ Structure-Based Drug Discovery (w/ Schrödinger) ] ➡️ [ Lead Candidate Selection ] ➡️ [ Phase 1/2 Clinical Trials ] ➡️ [ Phase 3 Pivotal Trials ] ➡️ [ FDA Approval ] ➡️ [ Commercialization or Partnership/Licensing ]

Structure Therapeutics has no approved products and generates no product revenue — its economics today come from collaboration and licensing deals (Schrödinger, Genentech/Roche) layered on top of continued clinical development funded by its cash balance and capital markets access.

---

2. Business Segments / Pipeline

Structure Therapeutics is a single-business clinical-stage biopharma; its "segments" are best understood as parallel drug programs rather than reporting segments.

┌─────────────────────────────────────────┐
│          Structure Therapeutics             │
└──────────────────┬────────────────────────────┘
                    │
      ┌─────────────┼─────────────┐
      ▼             ▼             ▼
┌───────────┐ ┌───────────────┐ ┌─────────────────┐
│ GLP-1R      │ │ Amylin (DACRA) │ │ Early/Discovery   │
│ Program     │ │ Program         │ │ (GIPR, GCGR,       │
│ (aleniglipron│ │ (ACCG-2671,     │ │ LTSE-2578)          │
│ /GSBR-1290) │ │ ACCG-3535)      │ │                     │
└───────────┘ └───────────────┘ └─────────────────┘

GLP-1R Program (lead asset)

Aleniglipron is in Phase 2 with Phase 3 planned for H2 2026 following an End-of-Phase 2 FDA meeting. 44-week topline data from the exploratory ACCESS II study are expected in Q1 2026.

Amylin (DACRA) Program

ACCG-2671 (lead candidate) began Phase 1 in December 2025; ACCG-3535 (second candidate) Phase 1 is planned for H2 2026. Amylin agonism is an emerging complementary mechanism to GLP-1 in obesity treatment, mirrored by combination approaches elsewhere in the industry.

Early/Discovery Programs

GIPR and GCGR discovery programs are being explored for combination use; LTSE-2578 (an LPA1R antagonist for idiopathic pulmonary fibrosis) completed Phase 1 in July 2025, with the company now considering strategic alternatives for that asset outside its core metabolic focus.

---

3. Product Portfolio (Pipeline Table)

---

4. Competitive Landscape

No oral small-molecule GLP-1R therapy is yet approved for diabetes or obesity, so the competitive race is still open. Structure Therapeutics competes against other oral small-molecule GLP-1R developers, including Pfizer, Eli Lilly, Terns Pharmaceuticals, and Merck (which licensed its candidate from Hansoh), while the injectable incumbents — Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, and Kailera — set the efficacy and commercial bar the oral entrants must clear or meaningfully differentiate against on convenience.

                High Clinical Progress
                        │
   Eli Lilly (oral      │   Pfizer (discontinued
   orforglipron) ●       │   earlier oral candidates) ●
                        │
Injectable ──────────────┼────────────── Oral
                        │
   Novo Nordisk /         │   Structure Therapeutics ●
   Eli Lilly (injectable) │   (aleniglipron)
                Low Clinical Progress (earlier stage)

---

5. Strategic Strengths & Risks

Strengths

• Differentiated "biased agonist" mechanism: Aleniglipron is designed to separate therapeutic G-protein signaling from side-effect-associated β-arrestin signaling — a scientifically meaningful, patent-protected differentiation if it holds up in Phase 3.
• Strong efficacy signal to date: Up to 15.3% placebo-adjusted weight loss at 36 weeks (ACCESS II, 240mg) is competitive with early data from other oral GLP-1 programs.
• Platform monetization: The Genentech/Roche CT-996 license ($100M upfront, December 2025) and ongoing Schrödinger collaboration milestones demonstrate the broader discovery platform has value beyond the lead asset alone.
• Extended cash runway: Reported cash runway through 2028 as of 2026 reduces near-term financing risk relative to typical clinical-stage biotechs.

Risks

• Crowded, well-funded competitive field: Eli Lilly's oral orforglipron and other large-pharma programs have far greater commercial and manufacturing resources.
• Binary clinical/regulatory risk: Phase 3 results and eventual FDA approval are not guaranteed, and the company's own 10-K flags internal inconsistency between describing aleniglipron as being in "five ongoing clinical studies" in one section versus "two Phase 2 clinical studies" elsewhere — a reminder to read primary trial data carefully rather than relying on any single summary.
• No current product revenue: All economics depend on either eventual approval/commercialization or continued licensing deals.
• Manufacturing scale-up risk: The company's planned 6,000 tons/year manufacturing capacity target is still a forward-looking commitment, not an operating reality.

---

6. Financial Overview

---

7. Summary Conclusion

Structure Therapeutics' moat, such as it exists at this stage, is scientific and IP-based: a differentiated biased-agonist mechanism and a 480-plus patent estate around oral small-molecule GPCR chemistry, validated externally by a $100 million Genentech licensing deal. The business has no product revenue yet and faces extremely well-capitalized competitors racing toward the same oral-GLP-1 prize, so the entire investment case rests on Phase 3 trial execution (starting H2 2026) and eventual regulatory approval — a binary, multi-year outcome that is still genuinely uncertain despite encouraging Phase 2 efficacy data.